Prognostic significance of 68Ga-Pentixafor PET/CT in multiple myeloma recurrence: a comparison to 18F-FDG PET/CT and laboratory results

被引:26
作者
Kuyumcu, Serkan [1 ]
Isik, Emine Goknur [1 ]
Tiryaki, Tarik Onur [2 ]
Has-Simsek, Duygu [1 ]
Sanli, Yasemin [1 ]
Buyukkaya, Fikret [1 ]
Ozkan, Zeynep Gozde [1 ]
Kalayoglu-Besisik, Sevgi [2 ]
Unal, Seher Nilgun [1 ]
机构
[1] Istanbul Med Fac, Dept Nucl Med, Istanbul, Turkey
[2] Istanbul Med Fac, Dept Internal Med, Div Hematol, Istanbul, Turkey
关键词
CXCR4; PET; Multiple myeloma; Pentixafor; FDG; POSITRON-EMISSION-TOMOGRAPHY; RECEPTOR CXCR4 EXPRESSION; EXTRAMEDULLARY DISEASE; COMPUTED TOMOGRAPHY; BONE-DISEASE; THERAPY; DIAGNOSIS; SURVIVAL; FEATURES; FDG;
D O I
10.1007/s12149-021-01652-1
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose This study investigates the prognostic value of Ga-68-Pentixafor PET/CT using PET-derived quantitative in multiple myeloma (MM) patients with suspected recurrence in comparison to F-18-FDG PET/CT and clinical data. Methods Twenty-four MM patients with suspicion for relapse who underwent Ga-68-Pentixafor and F-18-FDG PET/CT were retrospectively evaluated. Total bone marrow glycolysis for F-18-FDG (TBMFDG) and total bone marrow uptake for Ga-68-Pentixafor PET/CT (TBMCXCR4) were calculated using whole-body metabolic tumor burden obtained by dedicated software (MIM 7.0.6). The patients were followed for 19-24 months, and the association of PET-derived quantitative data with overall survival (OS) was analyzed. Results Ga-68-Pentixafor PET/CT was positive in 17 patients, of which 13 were also positive on F-18-FDG PET/CT, whereas 7 patients were negative on both scans. The positive rate of Ga-68-Pentixafor and F-18-FDG PET/CT on a patient-based approach was 70.8% and 54.1%, respectively. Ga-68-Pentixafor positivity was significantly associated with OS (p = 0.009), and F-18-FDG positivity was at the margin of statistical significance (p = 0.056). TBMCXCR4 and TBMFDG were negatively correlated with OS (r = -0.457, p = 0.025 and r = -0.617, p = 0.001, respectively). The OS was negatively correlated with beta-2-microglobulin levels (r = -0.511, p = 0.01) and CRAB score (r = -0.592, p = 0.002) as an indicator of the end-organ disease, which confirmed these results. Serum beta-2-microglobulin levels and CRAB score were also correlated with TBMCXCR4 (r = 0.442, p = 0.039 and r = 0.573, p = 0.003, respectively) and TBMFDG (r = 0.543, p = 0.009 and r = -0.424, p = 0.003, respectively). Conclusion Ga-68-Pentixafor PET/CT positivity is a negative prognostic factor in the survival outcome of MM patients. Complementary Ga-68-Pentixafor PET/CT has the potential to overcome F-18-FDG PET/CT limitations and helps a more precise risk stratification.
引用
收藏
页码:1147 / 1156
页数:10
相关论文
共 28 条
  • [1] Role of imaging in multiple myeloma
    Baffour, Francis I.
    Glazebrook, Katrina N.
    Kumar, Shaji K.
    Broski, Stephen M.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (08) : 966 - 977
  • [2] Cancer and the chemokine network
    Balkwill, F
    [J]. NATURE REVIEWS CANCER, 2004, 4 (07) : 540 - 550
  • [3] CXCR4 is a good survival prognostic indicator in multiple myeloma patients
    Bao, Li
    Lai, Yueyun
    Liu, Yanrong
    Qin, Yazhen
    Zhao, Xiaosu
    Lu, Xijing
    Jiang, Qian
    Lu, Jin
    Huang, Xiaojun
    [J]. LEUKEMIA RESEARCH, 2013, 37 (09) : 1083 - 1088
  • [4] F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma
    Bartel, Twyla B.
    Haessler, Jeff
    Brown, Tracy L. Y.
    Shaughnessy, John D., Jr.
    van Rhee, Frits
    Anaissie, Elias
    Alpe, Terri
    Angtuaco, Edgardo
    Walker, Ronald
    Epstein, Joshua
    Crowley, John
    Barlogie, Bart
    [J]. BLOOD, 2009, 114 (10) : 2068 - 2076
  • [5] Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group
    Cavo, Michele
    Terpos, Evangelos
    Nanni, Cristina
    Moreau, Philippe
    Lentzsch, Suzanne
    Zweegman, Sonja
    Hillengass, Jens
    Engelhardt, Monika
    Usmani, Saad Z.
    Vesole, David H.
    San-Miguel, Jesus
    Kumar, Shaji K.
    Richardson, Paul G.
    Mikhael, Joseph R.
    da Costa, Fernando Leal
    Dimopoulos, Meletios-Athanassios
    Zingaretti, Chiara
    Abildgaard, Niels
    Goldschmidt, Hartmut
    Orlowski, Robert Z.
    Chng, Wee Joo
    Einsele, Hermann
    Lonial, Sagar
    Barlogie, Bart
    Anderson, Kenneth C.
    Rajkumar, S. Vincent
    Durie, Brian G. M.
    Zamagni, Elena
    [J]. LANCET ONCOLOGY, 2017, 18 (04) : E206 - E217
  • [6] Combining FDG-PET/CT with laboratory data yields superior results for prediction of relapse in multiple myeloma*
    Elliott, Brian M.
    Peti, Steven
    Osman, Keren
    Scigliano, Eileen
    Lee, David
    Isola, Luis
    Kostakoglu, Lale
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2011, 86 (04) : 289 - 298
  • [7] Interest of Pet Imaging in Multiple Myeloma
    Jamet, Bastien
    Bailly, Clement
    Carlier, Thomas
    Touzeau, Cyrille
    Nanni, Cristina
    Zamagni, Elena
    Barre, Louisa
    Michaud, Anne-Victoire
    Cherel, Michel
    Moreau, Philippe
    Bodet-Milin, Caroline
    Kraeber-Bodere, Francoise
    [J]. FRONTIERS IN MEDICINE, 2019, 6
  • [8] Multiple myeloma epidemiology and survival: A unique malignancy
    Kazandjian, Dickran
    [J]. SEMINARS IN ONCOLOGY, 2016, 43 (06) : 676 - 681
  • [9] CXCR4-directed theranostics in oncology and inflammation
    Kircher, Malte
    Herhaus, Peter
    Schottelius, Margret
    Buck, Andreas K.
    Werner, Rudolf A.
    Wester, Hans-Juergen
    Keller, Ulrich
    Lapa, Constantin
    [J]. ANNALS OF NUCLEAR MEDICINE, 2018, 32 (08) : 503 - 511
  • [10] International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
    Kumar, Shaji
    Paiva, Bruno
    Anderson, Kenneth C.
    Durie, Brian
    Landgren, Ola
    Moreau, Philippe
    Munshi, Nikhil
    Lonial, Sagar
    Blade, Joan
    Mateos, Maria-Victoria
    Dimopoulos, Meletios
    Kastritis, Efstathios
    Boccadoro, Mario
    Orlowski, Robert
    Goldschmidt, Hartmut
    Spencer, Andrew
    Hou, Jian
    Chng, Wee Joo
    Usmani, Saad Z.
    Zamagni, Elena
    Shimizu, Kazuyuki
    Jagannath, Sundar
    Johnsen, Hans E.
    Terpos, Evangelos
    Reiman, Anthony
    Kyle, Robert A.
    Sonneveld, Pieter
    Richardson, Paul G.
    McCarthy, Philip
    Ludwig, Heinz
    Chen, Wenming
    Cavo, Michele
    Harousseau, Jean-Luc
    Lentzsch, Suzanne
    Hillengass, Jens
    Palumbo, Antonio
    Orfao, Alberto
    Rajkumar, S. Vincent
    Miguel, Jesus San
    Avet-Loiseau, Herve
    [J]. LANCET ONCOLOGY, 2016, 17 (08) : E328 - E346